132 related articles for article (PubMed ID: 37438082)
21. Oxaliplatin and 5-FU/folinic acid (modified FOLFOX6) with or without aflibercept in first-line treatment of patients with metastatic colorectal cancer: the AFFIRM study.
Folprecht G; Pericay C; Saunders MP; Thomas A; Lopez Lopez R; Roh JK; Chistyakov V; Höhler T; Kim JS; Hofheinz RD; Ackland SP; Swinson D; Kopp M; Udovitsa D; Hall M; Iveson T; Vogel A; Zalcberg JR
Ann Oncol; 2016 Jul; 27(7):1273-9. PubMed ID: 27091810
[TBL] [Abstract][Full Text] [Related]
22. Efficacy of DC-CIK Immunotherapy Combined with Chemotherapy on Locally Advanced Gastric Cancer.
Liu G; Chen D; Zhao X; You X; Huang C; Cheng Z; Mao X; Zhou H
J Oncol; 2022; 2022():5473292. PubMed ID: 35865086
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of mFOLFOX6 plus bevacizumab regimen in advanced colorectal cancer after deep hyperthermia: a single-center retrospective study.
Han G; Cui L; Sun C; Yu L; Liu S
Front Oncol; 2023; 13():1259713. PubMed ID: 38125935
[TBL] [Abstract][Full Text] [Related]
24. Cord blood-derived cytokine-induced killer cells biotherapy combined with second-line chemotherapy in the treatment of advanced solid malignancies.
Niu Q; Wang W; Li Y; Qin S; Wang Y; Wan G; Guan J; Zhu W
Int Immunopharmacol; 2011 Apr; 11(4):449-56. PubMed ID: 21215350
[TBL] [Abstract][Full Text] [Related]
25. Autologous cytokine-induced killer cell therapy in lung cancer patients: a retrospective study.
Zhang J; Zhu L; Du H; He X; Yin Y; Gu Y; Liu L; Lu K; Guo R; Liu P; Shu Y
Biomed Pharmacother; 2015 Mar; 70():248-52. PubMed ID: 25776508
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and Long-term Peripheral Sensory Neuropathy of 3 vs 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Colon Cancer: The ACHIEVE Phase 3 Randomized Clinical Trial.
Yoshino T; Yamanaka T; Oki E; Kotaka M; Manaka D; Eto T; Hasegawa J; Takagane A; Nakamura M; Kato T; Munemoto Y; Takeuchi S; Bando H; Taniguchi H; Gamoh M; Shiozawa M; Mizushima T; Saji S; Maehara Y; Ohtsu A; Mori M
JAMA Oncol; 2019 Nov; 5(11):1574-1581. PubMed ID: 31513248
[TBL] [Abstract][Full Text] [Related]
27. [Clinical Analysis of Autologous Cytokine-induced Killer Cells Combined with IL-2 for Treating of Elderly Patients with B-cell Malignant Lymphoma].
Wu Y; Shi L; Feng L; Lv DL
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Jun; 24(3):738-43. PubMed ID: 27342501
[TBL] [Abstract][Full Text] [Related]
28. [Therapeutic effect of mFOLFOX6 for synchronous unresectable liver metastases from colorectal cancer].
Chikatani K; Ishibashi K; Tajima Y; Hatano S; Amano K; Ishiguro T; Kuwabara K; Sobajima J; Ohsawa T; Okada N; Kumamoto K; Haga N; Iwama T; Ishida H
Gan To Kagaku Ryoho; 2011 Nov; 38(12):2211-3. PubMed ID: 22202333
[TBL] [Abstract][Full Text] [Related]
29. Immunotherapy with cytokine-induced killer cells as an adjuvant treatment for advanced gastric carcinoma: a retrospective study of 165 patients.
Zhao H; Fan Y; Li H; Yu J; Liu L; Cao S; Ren B; Yan F; Ren X
Cancer Biother Radiopharm; 2013 May; 28(4):303-9. PubMed ID: 23506427
[TBL] [Abstract][Full Text] [Related]
30. Intermittent Withdrawal of Oxaliplatin for Alleviating Neurotoxicity during Oxaliplatin-Based Chemotherapy for Japanese Patients with Inoperable or Metastatic Colorectal Cancer: A Phase 2 Multicenter Study.
Kato S; Imai H; Gamoh M; Takahata T; Ohori H; Yasuda K; Niitani T; Murakawa Y; Amagai K; Isobe H; Shindo Y; Kuroki M; Sakamoto Y; Shimodaira H; Yoshioka T; Ishioka C
Tohoku J Exp Med; 2018 May; 245(1):21-28. PubMed ID: 29743448
[TBL] [Abstract][Full Text] [Related]
31. Effects of cytokine-induced killer cell treatment in colorectal cancer patients: a retrospective study.
Zhang J; Zhu L; Zhang Q; He X; Yin Y; Gu Y; Guo R; Lu K; Liu L; Liu P; Shu Y
Biomed Pharmacother; 2014 Jul; 68(6):715-20. PubMed ID: 25107840
[TBL] [Abstract][Full Text] [Related]
32. Efficacy of dendritic cell-cytokine induced killer cells combined with concurrent chemoradiotherapy on locally advanced non-small cell lung cancer.
Tian L; Wang W; Yu B; Zhang G
J BUON; 2020; 25(5):2364-2370. PubMed ID: 33277857
[TBL] [Abstract][Full Text] [Related]
33. Capecitabine metronomic chemotherapy combined with autologous CIK cell immunotherapy in the treatment of recurrent and metastatic triple-negative breast cancer.
Chen S; Yang Y; Jiao Y; Sun H; Yan Z
J BUON; 2021; 26(3):734-740. PubMed ID: 34268928
[TBL] [Abstract][Full Text] [Related]
34. Effect of RFA and TACE combined with postoperative cytokine-induced killer cell immunotherapy in primary hepatocellular carcinoma.
Ji Q; Fu Y; Zhu X; Wang L; Ling C
J BUON; 2021; 26(1):235-242. PubMed ID: 33721457
[TBL] [Abstract][Full Text] [Related]
35. Regulatory (FoxP3+) T-cell tumor infiltration is a favorable prognostic factor in advanced colon cancer patients undergoing chemo or chemoimmunotherapy.
Correale P; Rotundo MS; Del Vecchio MT; Remondo C; Migali C; Ginanneschi C; Tsang KY; Licchetta A; Mannucci S; Loiacono L; Tassone P; Francini G; Tagliaferri P
J Immunother; 2010 May; 33(4):435-41. PubMed ID: 20386463
[TBL] [Abstract][Full Text] [Related]
36. Effects of mFOLFOX6 regimen combined with carrelizumab on immune function and prognosis in patients with microsatellite instability colorectal cancer.
Sun J; Yao N; Lu P; Wang Y
Cell Mol Biol (Noisy-le-grand); 2022 Feb; 67(5):356-362. PubMed ID: 35818232
[TBL] [Abstract][Full Text] [Related]
37. Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G).
Yamazaki K; Nagase M; Tamagawa H; Ueda S; Tamura T; Murata K; Eguchi Nakajima T; Baba E; Tsuda M; Moriwaki T; Esaki T; Tsuji Y; Muro K; Taira K; Denda T; Funai S; Shinozaki K; Yamashita H; Sugimoto N; Okuno T; Nishina T; Umeki M; Kurimoto T; Takayama T; Tsuji A; Yoshida M; Hosokawa A; Shibata Y; Suyama K; Okabe M; Suzuki K; Seki N; Kawakami K; Sato M; Fujikawa K; Hirashima T; Shimura T; Taku K; Otsuji T; Tamura F; Shinozaki E; Nakashima K; Hara H; Tsushima T; Ando M; Morita S; Boku N; Hyodo I
Ann Oncol; 2016 Aug; 27(8):1539-46. PubMed ID: 27177863
[TBL] [Abstract][Full Text] [Related]
38. Phase II trial of an alternating regimen consisting of first-line mFOLFOX6 plus bevacizumab and FOLFIRI plus bevacizumab for patients with metastatic colorectal cancer: FIREFOX plus bevacizumab trial (KSCC0801).
Miwa K; Oki E; Emi Y; Saeki H; Kusumoto T; Akagi Y; Ogata Y; Samura H; Tokunaga S; Ishikawa H; Tanaka T; Sueyoshi S; Higashi H; Matsuda H; Touyama T; Maehara Y;
Int J Clin Oncol; 2016 Feb; 21(1):110-7. PubMed ID: 26037783
[TBL] [Abstract][Full Text] [Related]
39. Effectiveness and safety of chemotherapy with cytokine-induced killer cells in non-small cell lung cancer: A systematic review and meta-analysis of 32 randomized controlled trials.
Xiao Z; Wang CQ; Feng JH; Zhou MH; Wang YZ; Li NN; Sun YP; Liu SY; Yao XS; Li CW; Ma B; Ding J; Chen L
Cytotherapy; 2019 Feb; 21(2):125-147. PubMed ID: 30554868
[TBL] [Abstract][Full Text] [Related]
40. Feasibility of mFOLFOX6 as the adjuvant treatment after curative resection of metastases from colorectal cancer in Japanese patients.
Machida N; Yoshizaki K; Boku N; Yamazaki K; Onozawa Y; Fukutomi A; Yasui H; Taku K
Int J Clin Oncol; 2013 Apr; 18(2):279-84. PubMed ID: 22367535
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
